I forsøgene til forebyggelse af osteoporose var den procentdel af forsøgs - personer, som oplevede en forøgelse eller en reduktion af BMD under behandling med raloxifen, henholdsvis 63% og 37% for rygsøjlen og henholdsvis 71% og 29% for hoften.
In the prevention trials, the percentage of subjects experiencing an increase or decrease in BMD during raloxifene therapy was: for the spine 37% decreased and 63% increased; and for the total hip 29% decreased and 71% increased.